DEF: Protagonist Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Protagonist Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 20, 2025, covering director elections, executive compensation, and auditor ratification.

Summary

• Protagonist Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 20, 2025, at 10:00 a.m. Pacific Time.
• Stockholders of record as of April 23, 2025, are eligible to vote.
• The meeting agenda includes the election of two Class III directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2025.
• The Board recommends voting 'FOR ALL' director nominees and 'FOR' the proposals regarding executive compensation and auditor ratification.
• The company has retained Innisfree M&A Incorporated to provide proxy solicitation and advisory services for a fee of approximately $40,000 plus expenses.
• The Notice, Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 2024 are available at www.proxyvote.com.
• The Board met five times during the last fiscal year.
• The company ended fiscal 2024 with cash, cash equivalents and marketable securities of approximately $559.2 million (not including the $165.0 million milestone payment received in January 2025), a significant increase from cash, cash equivalents and marketable securities of approximately $341.6 million as of December 31, 2023.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for the annual meeting. The company's financial position appears strong, contributing to a positive outlook.

Positives

• The company has significantly enhanced cash resources, ending fiscal 2024 with approximately $559.2 million in cash, cash equivalents, and marketable securities.
• The company received an upfront cash payment of $300 million in April 2024 from Takeda Pharmaceuticals USA, Inc.
• The company is eligible to receive up to $330 million in development, regulatory, and sales milestones from Takeda Pharmaceuticals USA, Inc.
• The company earned a $165.0 million milestone during Q4 2024 under the terms of the icotrokinra license and collaboration agreement with J&J Innovative Medicines (JNJ).

Risks

• The Proxy Statement contains forward-looking statements that are subject to risks and uncertainties.
• The company's actual results could differ materially from the forward-looking statements.

Future Outlook

The company expects to file New Drug Applications (NDA) submissions to the Food and Drug Administration in 2025.

Management Comments

• Dinesh V. Patel, Ph.D., President and Chief Executive Officer, invites stockholders to attend the 2025 Annual Meeting.

Industry Context

This proxy statement is a standard part of corporate governance, ensuring shareholders have the information needed to make informed decisions about the company's direction.

Comparison to Industry Standards

• The virtual meeting format aligns with current trends in corporate governance, increasing accessibility for stockholders.
• The company's use of an independent proxy solicitor is a common practice to ensure sufficient shareholder representation.
• The compensation peer group includes Agios Pharmaceuticals, Inc., Keros Therapeutics, Inc., Akero Therapeutics, Inc., Kura Oncology, Inc., bluebird bio, Inc., Morphic Holding, Inc., Celldex Therapeutics, Inc., Nurix Therapeutics, Inc., Cogent Biosciences, Inc., RAPT Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Replimune Group, Inc., CymaBay Therapeutics, Inc., Structure Therapeutics, Inc., Disc Medicine, Inc., Syndax Pharmaceuticals, Inc., Geron Corporation, Ventyx Biosciences, Inc., Hillevax, Inc., Viridian Therapeutics, Inc., IDEAYA Biosciences, Inc., Xencor, Inc., and Inhibrx Biosciences, Inc.

Stakeholder Impact

• Shareholders can participate in the company's governance by voting on key proposals.
• The outcome of the votes will influence the company's direction and executive compensation.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 20, 2025.
• The company will file the final voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Director Election, Executive Compensation, Auditor Ratification, Protagonist Therapeutics